Validation of simplified quantitative methods for 3*deoxy-3*-[18F]fluorothymidine Positron Emission Tomography ([18F]FLT PET) in patients with non-small cell lung cancer treated with tyrosine kinase inhibitor (gefitinib of erlotinib).
Completed
- Conditions
- lung cancer10029107non small cell lung cancer
- Registration Number
- NL-OMON36853
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
* Patient age 18 years or older
* Histological diagnosis of NSCLC
* Active EGFR-TK mutation
* Scheduled for treatment with gefitinib or erlotinib
* Tumour diameter > 3cm (to minimize partial volume effects) within the chest
* Able to remain supine for 90 minutes in the PET-CT scanner
* Written informed consent
Exclusion Criteria
* Pregnant or lactating patients
* Metal implants (e.g. pacemakers)
* Body weight > 100 kg
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The study parameters are the results of the simplified measures and the<br /><br>pharmacokinetic modeling of [18F]FLT PET prior to therapy and during treatment<br /><br>with gefitinib or erlotinib. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary, nonlinear kinetic filtering will be evaluated and perfusion measured<br /><br>with [15O]H2O PET.</p><br>